We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guideline Defines Informal, Formal Orphan Product Meetings
FDA Guideline Defines Informal, Formal Orphan Product Meetings
The FDA is clarifying when drugmakers should seek formal and informal presubmission meetings with the Office of Orphan Products Development, in an effort to save time and resources.